Open AccessFirst-line therapy of advanced head and neck cancer with double checkpoint blockade and radioimmunotherapy - first results.
Author(s) -
Antoniu Oreste Gostian,
Markus Eckstein,
Sandra Rutzner,
Jens von der Grün,
Thomas Illmer,
Matthias G. Hautmann,
Thomas Brunner,
Simon Laban,
Günther Klautke,
Benjamin Frey,
Arndt Hartmann,
Wilfried Budach,
Sabine Semrau,
Udo S. Gaipl,
Heinrich Iro,
Markus Hecht
Publication year - 2021
Publication title -
laryngo-, rhino-, otologie
Language(s) - English
Resource type - Conference proceedings
eISSN - 1438-8685
pISSN - 0935-8943
DOI - 10.1055/s-0041-1727929
Subject(s) - radioimmunotherapy , medicine , durvalumab , docetaxel , oncology , head and neck cancer , leukopenia , tremelimumab , cancer , radiation therapy , immunotherapy , chemotherapy , nivolumab , immunology , antibody , ipilimumab , monoclonal antibody